Vir Biotechnology (VIR) Projected to Post Earnings on Wednesday

Key Points

• Vir Biotechnology is expected to report its Q2 2025 earnings on August 6th, with analysts predicting an earnings loss of ($0.83) per share and revenue of $2.38 million.
• The company recently had a significant drop in revenue, with a 94.6% year-over-year decrease, reporting $3.03 million in the last quarter compared to an estimated $8.59 million.
• Despite a challenging financial landscape, several analysts maintain a positive outlook, with a consensus price target of $30.25 and seven buy ratings for the stock.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 6th. Analysts expect Vir Biotechnology to post earnings of ($0.83) per share and revenue of $2.38 million for the quarter.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.05). The business had revenue of $3.03 million during the quarter, compared to analyst estimates of $8.59 million. Vir Biotechnology had a negative net margin of 2,769.04% and a negative return on equity of 47.46%. The company's revenue for the quarter was down 94.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.48) earnings per share. On average, analysts expect Vir Biotechnology to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vir Biotechnology Stock Performance

NASDAQ VIR traded down $0.04 during trading on Friday, reaching $5.03. The company's stock had a trading volume of 809,884 shares, compared to its average volume of 1,084,500. The firm has a market cap of $695.35 million, a price-to-earnings ratio of -1.19 and a beta of 1.18. Vir Biotechnology has a twelve month low of $4.32 and a twelve month high of $14.45. The business's fifty day moving average price is $5.30 and its 200-day moving average price is $6.67.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group dropped their price target on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Needham & Company LLC reiterated a "buy" rating and set a $14.00 price target on shares of Vir Biotechnology in a research note on Thursday, May 22nd. Finally, Raymond James Financial assumed coverage on shares of Vir Biotechnology in a research note on Friday, July 11th. They set an "outperform" rating on the stock. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $30.25.

Insider Transactions at Vir Biotechnology

In related news, Director Vicki L. Sato sold 22,000 shares of the business's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $5.10, for a total transaction of $112,200.00. Following the sale, the director owned 1,298,391 shares of the company's stock, valued at approximately $6,621,794.10. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Mark Eisner sold 6,796 shares of the business's stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $5.47, for a total transaction of $37,174.12. Following the sale, the executive vice president directly owned 108,204 shares in the company, valued at approximately $591,875.88. This represents a 5.91% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,582 shares of company stock worth $185,150. 16.00% of the stock is owned by insiders.

Institutional Trading of Vir Biotechnology

A number of institutional investors have recently added to or reduced their stakes in the stock. Woodline Partners LP lifted its holdings in shares of Vir Biotechnology by 245.6% in the first quarter. Woodline Partners LP now owns 466,737 shares of the company's stock valued at $3,024,000 after purchasing an additional 331,701 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Vir Biotechnology by 2,088.4% in the first quarter. AQR Capital Management LLC now owns 268,297 shares of the company's stock valued at $1,739,000 after purchasing an additional 256,037 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company's stock valued at $4,813,000 after purchasing an additional 225,544 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Vir Biotechnology in the first quarter valued at about $359,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Vir Biotechnology in the first quarter valued at about $335,000. Hedge funds and other institutional investors own 65.32% of the company's stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).